Homoserine and Threonine Peptide Assembly

Abstract

Drawing on our recent success with reagent-less peptide-bond formation through serine-based assembly reactions in organic solvent, their range has been expanded to threonine and homoserine (an aspartic acid precursor) in the N-terminal peptide. Amino acid scope available at the assembly C-terminus includes bulky residues not amenable to classical ligation methods, such as cysteine-based NCL in aqueous media. The method was used to assemble a snakebite-toxin-neutralizing peptide from opossums.

Key words

amides - amino acids - acylation - nucleophilic substitution - trans-esterification

• References and Notes

• 1 Pirrung MC. Schreihans RS. Eur. J. Org. Chem. 2016; 5633
• 2a Varfolomeev SD. Uporov IV. Fedorov EV. Biochemistry (Mosc). 2002; 67: 1099
• 2b Li W. Kinch LN. Karplus PA. Grishin NV. Protein Sci. 2015; 24: 1075
• 2c Agouridas V. El Mahdi O. Cargoët M. Melnyk O. Bioorg. Med. Chem. 2017; 25: 4938
• 3 Pirrung MC. Zhang F. Ambadi S. Ibarra-Rivera TR. Eur. J. Org. Chem. 2012; 4283
• 4a Pratt RC. Lohmeijer BG. G. Long DA. Waymouth RM. Hedrick JL. J. Am. Chem. Soc. 2006; 128: 4556
• 4b Kiesewetter MK. Scholten MD. Kirn N. Weber RL. Hedrick JL. Waymouth RM. J. Org. Chem. 2009; 74: 9490
• 5 Ac-Ala-Thr-OMe (3) Protocol A Threonine methyl ester (1 equiv) was dissolved in THF (1 M) and set to stir at room temperature. Acetyl alanine HIP ester (1.5 equiv) was added, followed by AcOH (0.2 equiv). The reaction was monitored by TLC. After completion, the mixture was concentrated in vacuo to afford a crude product that was purified by column chromatography. Protocol B Threonine methyl ester (1 equiv) was added to a microwave reaction vessel and dissolved in THF (1 M). Acetyl alanine HIP ester (1.5 equiv) was added, followed by AcOH (0.2 equiv), and sealed under air. The reaction was irradiated at 70 °C (300 W, 5 min ramp time, 250 psi max, with stirring on). The mixture was concentrated in vacuo to afford a crude product that was purified by column chromatography. Protocol A: 16 h (0.1508 g, 94%). Protocol B: 4 h (0.1606 g, 96%). Mp 146–149 °C. [α]_D ²⁵ –56.0 (c 0.519, MeOH). IR (neat): 3302, 3158, 3086, 2996, 2950, 2916, 2868, 2758, 1753, 1641, 1556, 1528, 1440, 1379, 1338, 1313, 1267, 1209, 1177, 1151, 1121, 1082, 1065, 1040, 1007, 992, 953, 937, 917, 896, 844, 778, 750, 699, 649, 602, 529, 460, 449 cm^–1. ¹H NMR (400 MHz, CDCl₃): δ = 6.62 (d, J = 7.3 Hz, NH), 4.68–4.52 (m, 2 H), 4.41–4.31 (m, 1 H), 3.78 (s, J = 6.2 Hz, 3 H), 2.01 (s, J = 8.4 Hz, 3 H), 1.92 (br s, OH), 1.45 (d, J = 7.0 Hz, 3 H), 1.22 (d, J = 6.5 Hz, 3 H). ¹³C NMR (101 MHz, CDCl₃): δ = 173.0, 171.4, 170.8, 68.3, 58.0, 52.8, 49.3, 23.3, 20.2, 19.0. HRMS: m/z calcd for C₁₀H₁₉N₂O₅[M + H]⁺: 247.1288; found: 247.1286.
• 6 Evans V. Mahon MF. Webster RL. Tetrahedron 2014; 70: 7593
• 7a Lipps B. J. Venomous Anim. Toxins 1999; 5: 56
• 7b Lipps BV. Lipps FW. US 5576297, 1996
• 7c Lipps BV. Toxin Rev. 2008; 81
• 8 Lipps B. J. Venomous Anim. Toxins 2000; 6: 77
• 9 Komives CF. Sancheza EE. Rathore AS. White B. Balderrama M. Suntravat M. Cifelli A. Joshi V. Biotechnol. Prog. 2017; 33: 81
• 10a Pattabiraman VR. Ogunkoya AO. Bode JW. Angew. Chem. Int. Ed. 2012; 51: 5114
• 10b Wucherpfennig TG. Rohrbacher F. Pattabiraman VR. Bode JW. Angew. Chem. Int. Ed. 2014; 53: 12244
• 11 Lee CL. Li X. Curr. Opin. Chem. Biol. 2014; 22: 108
• 12a Bray BL. Nat. Rev. Drug Discov. 2003; 2: 587
• 12b Schneider SE. Bray BL. Mader CJ. Friedrich PE. Anderson MW. Taylor TS. Boshernitzan N. Niemi TE. Fulcher BC. Whight SR. White JM. Greene RJ. Stoltenberg LE. Lichty M. J. Pept. Sci. 2005; 11: 744
• 12c Marx V. Chem. Eng. News 2005; 83: 16